TDMS Study 05109-14 Pathology Tables
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
FINAL #1/MICE
Facility: Battelle Columbus Laboratory
Chemical CAS #: 102-71-6
Lock Date: 05/31/01
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 1
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 7 6 4 7
Moribund Sacrifice 8 10 5 10
Accidently Killed 1
Survivors
Terminal Sacrifice 34 34 41 32
Natural Death 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (50) (50) (50)
Serosa, Inflammation, Chronic 1 [3.0]
Intestine Small, Duodenum (50) (50) (50) (50)
Epithelium, Necrosis 1 [1.0]
Intestine Small, Jejunum (50) (50) (50) (50)
Diverticulum 1 [2.0]
Ulcer 1 [3.0]
Peyer's Patch, Hyperplasia 1 [4.0]
Peyer's Patch, Inflammation, Suppurative 1 [3.0]
Serosa, Inflammation, Granulomatous 1 [2.0]
Liver (50) (50) (50) (50)
Angiectasis, Focal 1 [1.0]
Basophilic Focus 4 3 3
Clear Cell Focus 4 3 3 5
Eosinophilic Focus 16 22 28 32
Fibrosis, Focal 1 [2.0]
Hematopoietic Cell Proliferation 4 [1.0] 3 [1.7] 3 [1.7] 4 [2.8]
Hepatodiaphragmatic Nodule 2 [1.0]
Infiltration Cellular, Lymphoid 26 [1.0] 30 [1.2] 36 [1.2] 20 [1.1]
Inflammation, Chronic 14 [1.0] 27 [1.0] 22 [1.0] 15 [1.0]
Mixed Cell Focus 5 8 14 11
Necrosis, Focal 5 [1.4] 1 [1.0] 3 [2.3]
Vacuolization Cytoplasmic, Focal 8 [1.3] 1 [1.0] 6 [1.0] 6 [1.2]
Centrilobular, Cytomegaly, Diffuse 1 [3.0]
Centrilobular, Necrosis 1 [2.0] 1 [3.0]
Mesentery (11) (6) (4) (9)
Inflammation, Chronic 1 [2.0]
Fat, Necrosis 10 [2.5] 6 [2.2] 3 [2.3] 9 [2.3]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 2
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Lymphatic, Angiectasis 1 [2.0]
Oral Mucosa (26) (26) (31) (31)
Inflammation, Chronic 26 [1.5] 26 [1.7] 31 [1.7] 31 [1.5]
Pancreas (50) (50) (50) (50)
Acinus, Atrophy 1 [4.0] 3 [3.3] 1 [2.0]
Acinus, Hyperplasia 1 [2.0]
Duct, Cyst 1 [3.0] 2 [3.5] 1 [4.0]
Stomach, Forestomach (50) (50) (50) (50)
Inflammation, Chronic 1 [2.0] 1 [2.0]
Inflammation, Suppurative 1 [2.0]
Ulcer 1 [1.0] 2 [1.5]
Epithelium, Cyst 1 [2.0]
Epithelium, Hyperplasia, Focal 1 [2.0] 1 [3.0]
Epithelium, Mineralization 1 [1.0]
Stomach, Glandular (50) (50) (50) (50)
Inflammation, Acute 1 [1.0]
Ulcer 1 [2.0] 1 [2.0]
Epithelium, Cyst 1 [1.0] 1 [1.0]
Epithelium, Hyperplasia, Focal 1 [2.0] 1 [2.0] 1 [3.0]
Serosa, Inflammation, Chronic 1 [2.0]
Tooth (1)
Inflammation, Chronic 1 [2.0]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (50)
Aorta, Inflammation, Chronic 2 [1.0]
Aorta, Mineralization 1 [2.0] 2 [3.0]
Heart (50) (50) (50) (50)
Artery, Inflammation, Chronic 3 [1.0] 1 [1.0] 2 [2.0] 1 [1.0]
Atrium, Thrombosis 2 [4.0]
Myocardium, Degeneration 4 [2.0] 1 [3.0]
Myocardium, Inflammation, Acute 1 [1.0]
Myocardium, Inflammation, Chronic 1 [1.0]
Myocardium, Mineralization 1 [1.0] 2 [2.5]
Myocardium, Necrosis 1 [3.0]
Pericardium, Inflammation, Chronic 1 [2.0]
Valve, Inflammation 1 [4.0]
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 3
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Adrenal Cortex (50) (50) (50) (50)
Hematopoietic Cell Proliferation 1 [3.0]
Hyperplasia, Focal 1 [1.0] 1 [1.0]
Hypertrophy, Focal 2 [2.0] 1 [1.0] 1 [1.0]
Inflammation, Suppurative 1 [1.0]
Subcapsular, Hyperplasia 49 [1.7] 49 [2.0] 50 [1.9] 50 [1.9]
Adrenal Medulla (49) (50) (50) (50)
Hyperplasia, Focal 1 [2.0] 1 [2.0]
Infiltration Cellular, Histiocyte 1 [2.0]
Islets, Pancreatic (50) (50) (50) (50)
Hyperplasia 25 [1.3] 18 [1.4] 20 [1.5] 18 [1.3]
Parathyroid Gland (39) (41) (45) (46)
Cyst 1 [2.0]
Pituitary Gland (50) (50) (50) (50)
Angiectasis 1 [4.0]
Pars Distalis, Hyperplasia 11 [1.5] 3 [2.0] 9 [1.8] 12 [1.6]
Pars Intermedia, Hyperplasia 1 [2.0]
Thyroid Gland (50) (50) (50) (50)
Inflammation, Granulomatous 1 [1.0] 1 [1.0]
C-Cell, Hyperplasia 2 [2.0]
Follicle, Cyst 1 [2.0] 1 [2.0] 2 [1.5] 1 [2.0]
Follicular Cell, Necrosis 1 [1.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (49) (49) (49)
Cyst 2 [1.0] 1 [2.0]
Inflammation, Suppurative 1 [2.0]
Ovary (50) (50) (50) (50)
Angiectasis 2 [2.0] 2 [2.0]
Cyst 27 [1.7] 22 [2.0] 21 [2.0] 25 [2.0]
Mineralization 1 [2.0]
Thrombosis 1 [2.0] 3 [4.0] 1 [4.0]
Uterus (50) (50) (50) (50)
Angiectasis 1 [2.0] 2 [2.5] 2 [3.0] 2 [2.5]
Thrombosis 1 [3.0] 1 [4.0]
Endometrium, Hyperplasia, Cystic 49 [2.5] 48 [2.3] 47 [2.7] 47 [2.8]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 4
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Fibrosis 1 [1.0]
Myeloid Cell, Hyperplasia 1 [4.0]
Lymph Node (6) (7) (4) (6)
Deep Cervical, Hyperplasia, Lymphoid 1 [4.0]
Iliac, Hyperplasia, Lymphoid 1 [3.0] 1 [4.0]
Lumbar, Hyperplasia, Lymphoid 1 [3.0] 1 [4.0]
Lumbar, Inflammation, Acute 1 [3.0]
Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [3.0] 2 [2.5]
Renal, Hyperplasia, Lymphoid 1 [4.0]
Lymph Node, Mandibular (49) (50) (50) (50)
Hematopoietic Cell Proliferation 1 [2.0]
Hyperplasia, Lymphoid 1 [3.0] 2 [3.0]
Lymph Node, Mesenteric (50) (49) (48) (48)
Hyperplasia, Histiocytic 1 [3.0]
Spleen (50) (50) (49) (50)
Atrophy 1 [2.0] 2 [3.0] 1 [3.0] 1 [4.0]
Hematopoietic Cell Proliferation 32 [1.8] 24 [1.5] 30 [1.5] 33 [1.6]
Hyperplasia, Lymphoid 1 [1.0]
Thymus (49) (49) (49) (49)
Atrophy 13 [2.5] 17 [2.7] 19 [2.5] 16 [2.6]
Hyperplasia, Focal 1 [2.0]
Hyperplasia, Histiocytic 1 [4.0]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Duct, Dilatation 1 [1.0] 1 [1.0]
Skin (50) (50) (50) (50)
Epidermis, Hyperkeratosis 1 [1.0]
Epidermis, Hyperplasia 1 [1.0]
Epidermis, Inflammation, Suppurative 1 [2.0]
Epidermis, Ulcer 1 [4.0]
Site of Application - Epidermis,
Hyperkeratosis 3 [1.0]
Site of Application - Epidermis, Hyperplasia 14 [1.3] 50 [1.9] 46 [2.0] 50 [2.0]
Site of Application - Epidermis,
Inflammation, Suppurative 1 [2.0] 2 [2.0] 20 [1.5] 32 [2.2]
Site of Application - Epidermis, Ulcer 1 [3.0] 1 [3.0] 6 [1.5] 17 [1.6]
Subcutaneous Tissue, Edema 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 5
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Subcutaneous Tissue, Fibrosis 1 [3.0]
Subcutaneous Tissue, Inflammation, Chronic 1 [4.0]
Subcutaneous Tissue, Necrosis 1 [2.0]
Subcutaneous Tissue, Site of Application -
Dermis, Inflammation, Chronic 4 [1.8] 27 [1.1] 31 [1.6] 44 [1.8]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosis 7 [1.1] 6 [2.0] 13 [1.5] 10 [1.1]
Fracture 1 [1.0]
Hyperostosis 1 [2.0]
Cranium, Callus 1 [2.0]
Femur, Hyperostosis 1 [2.0]
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Cyst Epithelial Inclusion 1 [1.0]
Hydrocephalus 1 [1.0]
Artery, Inflammation, Chronic 1 [2.0]
Artery, Meninges, Inflammation, Chronic 1 [2.0]
Hypothalamus, Compression 3 [3.7] 1 [4.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Inflammation, Acute 1 [4.0]
Inflammation, Chronic 2 [1.0] 3 [1.0] 1 [1.0]
Inflammation, Granulomatous 1 [1.0]
Mineralization 2 [3.0]
Alveolar Epithelium, Hyperplasia, Focal 1 [1.0] 1 [1.0]
Bronchus, Hyperplasia, Focal 1 [1.0]
Bronchus, Hyperplasia, Lymphoid 1 [2.0]
Mediastinum, Inflammation, Chronic 1 [3.0]
Serosa, Inflammation, Chronic 1 [3.0]
Nose (50) (50) (50) (50)
Inflammation, Chronic 1 [1.0]
Sinus, Inflammation, Suppurative 1 [2.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 6
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 FEMALE 0 MG/KG 100 300 1000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (49) (50) (50) (50)
Degeneration 1 [1.0]
Inflammation, Chronic 1 [3.0]
Harderian Gland (49) (50) (50) (50)
Hyperplasia 4 [2.0] 3 [3.0] 4 [2.0] 5 [2.6]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hydronephrosis 1 [2.0]
Infarct 1 [1.0] 5 [1.4] 3 [1.0] 3 [1.0]
Metaplasia, Osseous 1 [1.0] 3 [1.0]
Nephropathy 24 [1.0] 18 [1.1] 23 [1.0] 20 [1.1]
Glomerulus, Amyloid Deposition 2 [3.0]
Glomerulus, Cyst 1 [2.0]
Papilla, Necrosis 1 [1.0] 1 [2.0] 1 [2.0]
Papilla, Renal Tubule, Atrophy 1 [1.0]
Pelvis, Inflammation, Granulomatous 1 [1.0]
Renal Tubule, Cyst 1 [1.0]
Renal Tubule, Cytoplasmic Alteration 1 [4.0]
Renal Tubule, Mineralization 1 [2.0]
Urinary Bladder (50) (50) (49) (49)
Cyst 1 [3.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 7
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 5 2 6 8
Natural Death 8 5 10 2
Survivors
Terminal Sacrifice 37 43 34 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (48) (49) (50) (47)
Necrosis 1 [4.0]
Intestine Large, Colon (50) (50) (50) (50)
Inflammation, Chronic 1 [3.0]
Goblet Cell, Hyperplasia 1 [4.0]
Intestine Large, Cecum (50) (50) (50) (50)
Hemorrhage 1 [4.0]
Intestine Small, Duodenum (50) (50) (50) (50)
Epithelium, Hyperplasia 1 [2.0]
Intestine Small, Jejunum (50) (50) (50) (50)
Diverticulum 1 [1.0]
Epithelium, Hyperplasia 1 [2.0]
Peyer's Patch, Hyperplasia, Lymphoid 1 [1.0] 1 [2.0]
Serosa, Inflammation, Granulomatous 1 [3.0]
Intestine Small, Ileum (50) (50) (50) (50)
Muscularis, Infiltration Cellular,
Mononuclear Cell 1 [2.0]
Liver (50) (50) (50) (50)
Basophilic Focus 2 6 3 2
Clear Cell Focus 19 23 14 11
Eosinophilic Focus 9 20 31 30
Fibrosis 1 [1.0]
Hematopoietic Cell Proliferation 3 [1.0] 4 [1.3] 1 [1.0] 2 [1.5]
Hepatodiaphragmatic Nodule 1 1
Infiltration Cellular, Lymphoid 3 [1.0] 2 [1.5] 2 [1.5] 3 [1.0]
Inflammation, Acute 1 [2.0]
Inflammation, Chronic 9 [1.0] 14 [1.1] 10 [1.0] 11 [1.0]
Mixed Cell Focus 13 11 15 8
Necrosis, Focal 4 [1.8] 3 [1.3] 7 [2.0] 6 [1.3]
Vacuolization Cytoplasmic, Focal 2 [1.0] 1 [1.0] 3 [1.0] 5 [1.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 8
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Centrilobular, Necrosis 1 [2.0] 1 [3.0]
Mesentery (3) (3) (5) (7)
Inflammation, Granulomatous 1 [1.0]
Artery, Inflammation, Chronic 1 [3.0]
Fat, Necrosis 3 [2.0] 3 [2.7] 4 [2.3] 5 [1.8]
Oral Mucosa (31) (26) (35) (30)
Inflammation, Chronic 31 [1.9] 26 [1.9] 35 [1.8] 30 [1.7]
Pancreas (50) (50) (50) (50)
Acinus, Atrophy 1 [1.0]
Duct, Cyst 1 [3.0]
Stomach, Forestomach (50) (50) (50) (50)
Inflammation, Suppurative 1 [2.0]
Ulcer 1 [2.0] 1 [2.0]
Epithelium, Cyst 1 [2.0]
Epithelium, Hyperplasia, Focal 3 [2.0] 3 [1.7] 2 [1.5]
Stomach, Glandular (50) (50) (50) (50)
Hyperplasia, Lymphoid 1 [2.0]
Ulcer 2 [2.0]
Epithelium, Hyperplasia, Focal 1 [2.0]
Glands, Ectasia 1 [1.0]
Tooth (19) (18) (14) (13)
Malformation 19 [2.2] 18 [1.8] 14 [2.0] 13 [1.3]
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (50) (50) (50) (50)
Aorta, Inflammation, Chronic 1 [1.0]
Aorta, Mineralization 1 [2.0]
Pulmonary Vein, Thrombosis 1 [2.0]
Heart (50) (50) (50) (50)
Infiltration Cellular, Mononuclear Cell 3 [1.0] 1 [2.0]
Inflammation, Acute 1 [3.0]
Inflammation, Chronic 2 [1.5]
Artery, Inflammation, Chronic 1 [1.0] 3 [2.0]
Atrium, Thrombosis 1 [4.0] 1 [4.0]
Coronary Artery, Inflammation, Chronic 1 [2.0]
Myocardium, Degeneration 1 [2.0]
Myocardium, Mineralization 1 [1.0] 1 [1.0] 2 [1.0]
Valve, Inflammation, Chronic 1 [3.0]
Ventricle, Thrombosis 1 [1.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 9
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Hyperplasia, Focal 8 [1.5] 4 [1.5] 3 [1.0] 1 [1.0]
Hypertrophy, Focal 16 [1.6] 21 [1.3] 10 [1.2] 10 [1.3]
Necrosis 1 [3.0]
Subcapsular, Hyperplasia 39 [1.2] 45 [1.2] 40 [1.5] 40 [1.3]
Zona Glomerulosa, Hyperplasia 2 [2.5] 3 [2.0] 1 [1.0]
Adrenal Medulla (50) (50) (50) (50)
Hyperplasia, Focal 2 [2.0]
Necrosis 1 [3.0]
Islets, Pancreatic (50) (50) (50) (50)
Hyperplasia 45 [2.2] 43 [2.0] 43 [1.9] 32 [1.6]
Pituitary Gland (50) (49) (49) (50)
Pars Distalis, Hyperplasia 1 [2.0] 2 [1.0] 1 [3.0]
Pars Intermedia, Hyperplasia 1 [2.0] 3 [2.3]
Thyroid Gland (50) (50) (49) (50)
Follicle, Cyst 1 [1.0] 1 [1.0] 1 [3.0]
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Coagulating Gland (1) (1)
Cyst 1 [1.0]
Epididymis (50) (50) (50) (50)
Granuloma Sperm 1 [3.0] 1 [2.0] 2 [2.0]
Inflammation, Chronic 1 [1.0]
Preputial Gland (50) (50) (50) (50)
Atrophy 1 [2.0]
Cyst 10 [1.9] 14 [2.1] 11 [2.1] 15 [2.1]
Inflammation, Chronic 1 [2.0] 2 [1.5]
Inflammation, Suppurative 1 [2.0] 3 [2.7]
Prostate (50) (50) (50) (50)
Hyperplasia 1 [2.0]
Seminal Vesicle (50) (50) (50) (50)
Atrophy 1 [2.0]
Hyperplasia 1 [1.0] 2 [1.0] 2 [2.0]
Testes (50) (50) (50) (50)
Inflammation, Granulomatous 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 10
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Germinal Epithelium, Atrophy 4 [1.3] 2 [1.0] 1 [1.0] 2 [1.0]
Germinal Epithelium, Mineralization 2 [1.5] 1 [1.0]
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mesenteric (50) (48) (48) (50)
Congestion 1 [3.0]
Hyperplasia, Lymphoid 1 [4.0]
Spleen (49) (50) (50) (50)
Atrophy 4 [3.5] 1 [3.0] 1 [2.0]
Hematopoietic Cell Proliferation 14 [1.6] 20 [1.5] 17 [1.7] 19 [1.5]
Lymphoid Follicle, Hematopoietic Cell
Proliferation 1 [1.0] 1 [2.0]
Red Pulp, Infiltration Cellular, Mononuclear
Cell 1 [2.0]
Thymus (48) (47) (48) (48)
Atrophy 38 [2.8] 37 [2.3] 37 [2.4] 38 [2.3]
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Dermis, Edema 1 [3.0]
Epidermis, Hyperkeratosis 1 [1.0]
Epidermis, Ulcer 1 [3.0]
Site of Application - Epidermis,
Hyperkeratosis 3 [1.0]
Site of Application - Epidermis, Hyperplasia 5 [1.2] 44 [1.5] 45 [2.0] 49 [2.7]
Site of Application - Epidermis,
Inflammation, Suppurative 1 [1.0] 11 [1.5] 33 [1.7] 42 [2.8]
Site of Application - Epidermis, Ulcer 3 [1.0] 20 [1.4] 47 [2.6]
Subcutaneous Tissue, Site of Application -
Dermis, Inflammation, Chronic 1 [1.0] 15 [1.1] 40 [1.6] 49 [2.5]
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrosis 1 [2.0]
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 11
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression 1 [3.0]
Spinal Cord (1)
Necrosis 1 [3.0]
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Infiltration Cellular, Lymphoid 1 [2.0]
Inflammation, Acute 1 [3.0]
Inflammation, Chronic 1 [2.0]
Inflammation, Granulomatous 2 [1.0]
Alveolar Epithelium, Hyperplasia, Focal 2 [1.0] 2 [1.5] 1 [1.0] 2 [1.5]
Bronchus, Hyperplasia, Focal 1 [2.0]
Perivascular, Infiltration Cellular, Lymphoid 1 [3.0]
Vein, Thrombosis 1 [2.0]
Nose (50) (50) (50) (50)
Inflammation, Suppurative 2 [1.0] 1 [1.0]
Polyp, Inflammatory 1 [3.0]
Respiratory Epithelium, Mineralization 1 [1.0]
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (50)
Degeneration 1 [4.0]
Cornea, Inflammation, Acute 1 [2.0]
Retrobulbar, Inflammation, Suppurative 1 [3.0]
Harderian Gland (50) (50) (49) (50)
Hyperplasia 3 [1.3] 5 [1.6] 6 [1.8] 7 [1.4]
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Hydronephrosis 1 [2.0]
Infarct 2 [1.5] 3 [1.0] 2 [1.0] 4 [1.5]
Inflammation, Acute 2 [2.5]
Metaplasia, Osseous 1 [1.0] 4 [1.0] 2 [1.0] 2 [1.0]
Nephropathy 39 [1.3] 42 [1.2] 37 [1.0] 40 [1.2]
Artery, Thrombosis 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 12
NTP Experiment-Test: 05109-14 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT18
Study Type: CHRONIC WITH AVERAGE SEVERITY GRADES[b] Date: 06/06/02
Route: SKIN APPLICATION TRIETHANOLAMINE Time: 08:45:51
____________________________________________________________________________________________________________________________________
MICE:B6C3F1 MALE 0 MG/KG 200 630 2000
MG/KG MG/KG MG/KG
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Capsule, Inflammation, Chronic 1 [2.0]
Glomerulus, Cyst 2 [2.5] 2 [2.0]
Papilla, Necrosis 1 [3.0]
Renal Tubule, Cyst 4 [2.3] 2 [1.5] 4 [1.3]
Renal Tubule, Hyperplasia 1 [1.0] 1 [1.0] 2 [1.5]
Urinary Bladder (50) (50) (50) (50)
Cyst 1 [4.0]
Inflammation, Acute 1 [2.0]
a Number of animals examined microscopically at site and number of animals with lesion
b Average severity grade (1-minimal;2-mild;3-moderate;4-marked)
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------